Dr. Melton: To me, the term “mucoadhesive” translates into a drop that might blur vision. Yet, if you look at the two Phase III studies, zero patients out of 203 in the first study and zero patients out of 206 in the second study had drug-related blurred vision, and that's on the active drug, which is pretty remarkable. 3–5 This has clinically been supported by my own experience putting patients on LE gel and not getting any negative feedback regarding blurred vision. It's a pretty viscous, mucoadhesive drop, and because of its adaptive viscosity characteristics, it is unique as a gel.
Transdermal patches can be a very precise time released method of delivering a drug. Cutting a patch in half might affect the dose delivered. The release of the active component from a transdermal delivery system (patch) may be controlled by diffusion through the adhesive which covers the whole patch, by diffusion through a membrane which may only have adhesive on the patch rim or drug release may be controlled by release from a polymer matrix. Cutting a patch might cause rapid dehydration of the base of the medicine and affect the rate of diffusion.